A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  European Journal of Cancer

• Publication date

  2013-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ejca.2012.12.019PMID 23352437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular functions of syndecan-1 in disease.

  2012cited by this paper
• Immunocytokines: a novel class of potent armed antibodies.

  2012cited by this paper
• BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

  2012cited by this paper
• Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients

  2012cited by this paper
• Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension

  2012cited by this paper
• SnapShot: Tumor angiogenesis.

  2012cited by this paper
• Heparan Sulfate Chains of Syndecan-1 Regulate Ectodomain Shedding*

  2012cited by this paper
• Towards new therapeutic approaches for malignant melanoma

  2011cited by this paper
• Beyond natural antibodies: the power of in vitro display technologies

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Tumor angiogenesis: molecular pathways and therapeutic targets

  2011cited by this paper
• Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells

  2011cited by this paper
• Proteoglycans in cancer biology, tumour microenvironment and angiogenesis

  2011cited by this paper
• A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

  2011cited by this paper
• Identification of a novel cell binding site of periostin involved in tumour growth.

  2011cited by this paper
• Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma

  2011cited by this paper
• A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-α2a as first line treatment in metastatic melanoma

  2010cited by this paper
• Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

  2010cited by this paper
• Proteoglycans in health and disease: the multiple roles of syndecan shedding

  2010cited by this paper
• Targeting angiogenesis in melanoma: prospects for the future

  2010cited by this paper
• Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

  2010cited by this paper
• Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

  2010cited by this paper
• Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.

  2010cited by this paper
• Syndecan-1 regulates αvβ3 and αvβ5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor

  2009cited by this paper
• Heparan Sulfate Proteoglycan Modulation of Wnt5A Signal Transduction in Metastatic Melanoma Cells*

  2009cited by this paper
• Natural killer cells kill human melanoma cells with characteristics of cancer stem cells.

  2009cited by this paper
• Syndecans as receptors and organizers of the extracellular matrix

  2009cited by this paper
• Biomarkers of response and resistance to antiangiogenic therapy

  2009cited by this paper
• Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in Myeloma*

  2008cited by this paper
• Heparanase Enhances Syndecan-1 Shedding

  2007cited by this paper
• Fibronectin as target for tumor therapy

  2006cited by this paper
• Mechanotransduction involving multimodular proteins: converting force into biochemical signals.

  2006cited by this paper
• Design, construction, and characterization of a large synthetic human antibody phage display library

  2005cited by this paper
• Tumour vascular targeting

  2005cited by this paper
• Heparanase Degrades Syndecan-1 and Perlecan Heparan Sulfate

  2004cited by this paper
• The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS.

  2003cited by this paper
• Angiogenesis: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma

  2003cited by this paper
• Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.

  2002cited by this paper
• Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening.

  2001cited by this paper
• Cloning and sequencing of human immunoglobulin λ. gene segments

  1993cited by this paper
• The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence.

  1992cited by this paper

• Exosomes derived from fibroblasts enhance skin wound angiogenesis by regulating HIF-1α/VEGF/VEGFR pathway

  2025influential citation
• Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies

  2025cites this paper
• Gene expression profiling of venous malformations identifies the role of SDC1 in venous endothelial cells

  2024cites this paper
• Engineering antibodies with cancer‐associated binding sites

  2024cites this paper
• Syndecan-1: a key player in health and disease

  2024cites this paper
• Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments

  2023cites this paper
• Scientific and clinical relevance of non-cellular tumor microenvironment components in ovarian cancer chemotherapy resistance.

  2023cites this paper
• Role of Syndecans in Ovarian Cancer: New Diagnostic and Prognostic Biomarkers and Potential Therapeutic Targets

  2023cites this paper
• Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential.

  2023cites this paper
• Midkine promotes metastasis and therapeutic resistance via mTOR/RPS6 in uveal melanoma.

  2022cites this paper
• Research Progress on the Role of SDC1 in Breast Cancer and Other Tumors

  2022cites this paper
• Targeting Syndecan-1: New Opportunities in Cancer Therapy.

  2022cites this paper
• The Role and Therapeutic Value of Syndecan-1 in Cancer Metastasis and Drug Resistance

  2022cites this paper
• Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes

  2021cites this paper
• Syndecans and Their Synstatins: Targeting an Organizer of Receptor Tyrosine Kinase Signaling at the Cell-Matrix Interface

  2021cites this paper
• Role of Syndecan-1 in Cancer Stem Cells

  2021cites this paper
• Syndecan-1 (CD138), Carcinomas and EMT

  2021cites this paper
• Syndecan-1 in the Tumor Microenvironment.

  2020cites this paper
• Heparan sulfate proteoglycans as targets for cancer therapy: a review

  2020cites this paper
• Cell-surface heparan sulfate proteoglycans as multifunctional integrators of signaling in cancer.

  2020cites this paper
• Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment

  2020cites this paper
• Tumor Microenvironment: Extracellular Matrix Components – Part B

  2020cites this paper
• Role of cell surface proteoglycans in cancer immunotherapy.

  2020cites this paper
• VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1

  2019cites this paper
• Identification of Key Genes and Pathways in Pancreatic Cancer Gene Expression Profile by Integrative Analysis

  2019cites this paper
• L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model

  2019cites this paper
• Extracellular matrix-cell interactions: Focus on therapeutic applications.

  2019cites this paper
• Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues

  2019cites this paper
• CD138/syndecan–1 in pancreatic solid and pseudopapillary neoplasms

  2018cites this paper
• The endothelial glycocalyx anchors von Willebrand factor fibers to the vascular endothelium.

  2018cites this paper
• Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy

  2018cites this paper
• Immunoregulatory properties of the cytokine IL-34

  2017cites this paper
• Syndecans – key regulators of cell signaling and biological functions

  2017cites this paper
• Killing two birds with one stone: dual blockade of integrin and FGF signaling through targeting syndecan-4 in postoperative capsular opacification

  2017cites this paper
• Evaluation of the C-domain of heparanase during AGE-induced macrophage inflammatory response

  2017cites this paper
• Generation and characterization of a human nanobody against VEGFR-2

  2016cites this paper
• Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins

  2016cites this paper
• Phenotypic screening: the future of antibody discovery.

  2016cites this paper
• Cell surface syndecan-1 contributes to binding and function of macrophage migration inhibitory factor (MIF) on epithelial tumor cells.

  2016cites this paper
• Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine

  2015cites this paper
• A cytoplasmic C-terminal fragment of syndecan-1 is generated by sequential proteolysis and antagonizes syndecan-1 dependent lung tumor cell migration

  2015cites this paper
• Advances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies.

  2015influential citation
• Selection of scFv Antibody Fragments Binding to Human Blood versus Lymphatic Endothelial Surface Antigens by Direct Cell Phage Display

  2015cites this paper
• Selection strategies for anticancer antibody discovery: searching off the beaten path.

  2015cites this paper
• Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts

  2015cites this paper
• Heparan sulfate proteoglycans and heparin regulate melanoma cell functions.

  2014cites this paper
• Syndecans as Modulators and Potential Pharmacological Targets in Cancer Progression

  2014cites this paper
• Expression of periostin and syndecan-1 in endometriosis

  2014cites this paper
• Review CD 138 ( syndecan-1 ) expression in health and disease

  2014cites this paper
• Cell–matrix interactions: focus on proteoglycan–proteinase interplay and pharmacological targeting in cancer

  2014cites this paper
• CD138 (syndecan-1) expression in health and disease.

  2014cites this paper
• The Role of Syndecan-1 in Cellular Signaling and its Effects on Heparan Sulfate Biosynthesis in Mesenchymal Tumors

  2013cites this paper